

**MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence
Data as of December 5, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site COVID-19 (Interim Visits Included)²

	Birmingham	Blantyre	Chiang Mai	Hillbrow, WRHI	Lima,San Miguel	Pittsburgh	San Francisco	All Sites
Participants Enrolled	33	31	30	30	30	33	30	217
1. Behavioral Assessment Required and Expected	14	109	56	65	4	16	0	264
Completed	14 (100.0%)	109 (100.0%)	56 (100.0%)	64 (98.5%)	2 (50.0%)	15 (93.8%)	0 (-%)	260 (98.5%)
Not Completed	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.5%)	2 (50.0%)	1 (6.3%)	0 (-%)	4 (1.5%)
2. In-depth Interview Required and Expected	9	79	34	44	1	12	0	179
Completed	8 (88.9%)	79 (100.0%)	34 (100.0%)	43 (97.7%)	1 (100.0%)	12 (100.0%)	0 (-%)	177 (98.9%)
Not Completed	1 (11.1%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	0 (0.0%)	0 (0.0%)	0 (-%)	2 (1.1%)
3. Physical Examination Required and Expected	0	8	0	6	0	0	0	14
Completed	0 (-%)	8 (100.0%)	0 (-%)	6 (100.0%)	0 (-%)	0 (-%)	0 (-%)	14 (100.0%)
4. Rectal Examination Required and Expected	9	87	34	51	1	12	0	194
Completed	0 (0.0%)	87 (100.0%)	28 (82.4%)	41 (80.4%)	1 (100.0%)	3 (25.0%)	0 (-%)	160 (82.5%)
Partially Completed	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.0%)	0 (0.0%)	1 (8.3%)	0 (-%)	2 (1.0%)
Not Completed	9 (100.0%)	0 (0.0%)	6 (17.6%)	9 (17.6%)	0 (0.0%)	8 (66.7%)	0 (-%)	32 (16.5%)
5. NAAT (Pharyngeal) for GC/CT Required and Expected	3	32	19	20	1	4	0	79
Completed	0 (0.0%)	32 (100.0%)	16 (84.2%)	20 (100.0%)	0 (0.0%)	1 (25.0%)	0 (-%)	69 (87.3%)
Not Completed	3 (100.0%)	0 (0.0%)	3 (15.8%)	0 (0.0%)	1 (100.0%)	3 (75.0%)	0 (-%)	10 (12.7%)
6. NAAT (Urine) for GC/CT Required and Expected	3	32	19	20	1	4	0	79
Completed	0 (0.0%)	32 (100.0%)	16 (84.2%)	20 (100.0%)	0 (0.0%)	1 (25.0%)	0 (-%)	69 (87.3%)
Not Completed	3 (100.0%)	0 (0.0%)	3 (15.8%)	0 (0.0%)	1 (100.0%)	3 (75.0%)	0 (-%)	10 (12.7%)
7. Pregnancy Test Required and Expected (For participants who can get pregnant only)	1	0	0	0	0	0	0	1
Not Completed	1 (100.0%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	1 (100.0%)
8. Plasma for Archive Required and Expected	0	4	0	3	0	0	0	7
Completed	0 (-%)	4 (100.0%)	0 (-%)	3 (100.0%)	0 (-%)	0 (-%)	0 (-%)	7 (100.0%)
9. Syphilis serology Required and Expected	3	32	19	20	1	4	0	79

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit.

If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

² Only visits completed or expected to be completed on or after 16 March 2020 are included in this report.

**MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence
Data as of December 5, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site COVID-19 (Interim Visits Included)²

	Birmingham	Blantyre	Chiang Mai	Hillbrow, WRHI	Lima,San Miguel	Pittsburgh	San Francisco	All Sites
Completed	0 (0.0%)	32 (100.0%)	16 (84.2%)	20 (100.0%)	1 (100.0%)	1 (25.0%)	0 (-%)	70 (88.6%)
Not Completed	3 (100.0%)	0 (0.0%)	3 (15.8%)	0 (0.0%)	0 (0.0%)	3 (75.0%)	0 (-%)	9 (11.4%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit.

If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

² Only visits completed or expected to be completed on or after 16 March 2020 are included in this report.

**MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence
Data as of December 5, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site COVID-19 (Interim Visits Included)²

	Birmingham	Blantyre	Chiang Mai	Hillbrow, WRHI	Lima,San Miguel	Pittsburgh	San Francisco	All Sites
10. HIV-1/2 Test Required and Expected	3	36	19	24	1	4	0	87
Completed	0 (0.0%)	36 (100.0%)	16 (84.2%)	24 (100.0%)	1 (100.0%)	1 (25.0%)	0 (-%)	78 (89.7%)
Not Completed	3 (100.0%)	0 (0.0%)	3 (15.8%)	0 (0.0%)	0 (0.0%)	3 (75.0%)	0 (-%)	9 (10.3%)
11. NAAT (Pelvic) for GC/CT/Trichomonas Required and Expected (For participants with vagina or neovagina)	1	0	0	0	0	0	0	1
Not Completed	1 (100.0%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	0 (-%)	1 (100.0%)
12. NAAT (Anorectal) for GC/CT Required and Expected	3	32	19	20	1	4	0	79
Completed	0 (0.0%)	32 (100.0%)	16 (84.2%)	20 (100.0%)	0 (0.0%)	1 (25.0%)	0 (-%)	69 (87.3%)
Not Completed	3 (100.0%)	0 (0.0%)	3 (15.8%)	0 (0.0%)	1 (100.0%)	3 (75.0%)	0 (-%)	10 (12.7%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit.

If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

² Only visits completed or expected to be completed on or after 16 March 2020 are included in this report.